Tamoxifen-Induced Non-alcoholic Steatohepatitis Cirrhosis
Soonchunhyang Medical Science
;
: 81-84, 2018.
Artículo
en Inglés
| WPRIM
| ID: wpr-715108
ABSTRACT
Non-alcoholic fatty liver disease has been observed in over 30% of patients who have received tamoxifen therapy. However, tamoxifen-induced non-alcoholic steatohepatitis (NASH) cirrhosis has never been reported in Korea. A 41-year-old woman was diagnosed with invasive ductal carcinoma in the left breast. She had well-controlled type 2 diabetes mellitus, hypertension, and chronic hepatitis B. Ultrasonography showed mild fatty liver. Chronic hepatitis B had been treated with clevudine one month before the diagnosis of breast cancer. The patient was diagnosed with NASH cirrhosis 39 months after tamoxifen treatment. Careful observation for the development of NASH cirrhosis is warranted during tamoxifen therapy.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Tamoxifeno
/
Fibrosis
/
Mama
/
Neoplasias de la Mama
/
Ultrasonografía
/
Hepatitis B Crónica
/
Carcinoma Ductal
/
Diabetes Mellitus Tipo 2
/
Diagnóstico
/
Hígado Graso
Tipo de estudio:
Estudio diagnóstico
Límite:
Adulto
/
Femenino
/
Humanos
País/Región como asunto:
Asia
Idioma:
Inglés
Revista:
Soonchunhyang Medical Science
Año:
2018
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS